Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015 (2015), Article ID 560938, 12 pages
http://dx.doi.org/10.1155/2015/560938
Review Article

Peripheral Signals Mediate the Beneficial Effects of Gastric Surgery in Obesity

1Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Travesía Choupana s/n, 15706 Santiago de Compostela, Spain
2Departamento de Pediatría, Universidad de Santiago de Compostela (USC), Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Travesía Choupana s/n, 15706 Santiago de Compostela, Spain
3CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Spain
4Departamento de Fisiología, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Avenida Barcelona s/n, 15782 Santiago de Compostela, Spain
5Laboratorio de Endocrinología Molecular y Celular, Universidad de Santiago de Compostela (USC), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Travesía Choupana s/n, 15706 Santiago de Compostela, Spain

Received 24 November 2014; Accepted 21 March 2015

Academic Editor: Takuji Tanaka

Copyright © 2015 Silvia Barja-Fernández et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, The SuRF Report 2, 2005.
  2. European-Commission, Strategy for Europe and Nutrition, Overweight and Obesity Related Health Issues—Implementation Progress Report 2010, European-Commission, 2010.
  3. Y. Wang and M. A. Beydoun, “The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis,” Epidemiologic Reviews, vol. 29, no. 1, pp. 6–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Rodgers, M. H. Tschöp, and J. P. H. Wilding, “Anti-obesity drugs: past, present and future,” Disease Models & Mechanisms, vol. 5, no. 5, pp. 621–626, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. W. Breaux, “Obesity surgery in children,” Obesity Surgery, vol. 5, no. 3, pp. 279–284, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. WHO, Obesity and Overweight-Fact Sheet, WHO, 2006.
  7. J. A. Rivera, S. Barquera, F. Campirano, I. Campos, M. Safdie, and V. Tovar, “Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity,” Public Health Nutrition, vol. 5, no. 1 A, pp. 113–122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. B. M. Popkin, L. S. Adair, and S. W. Ng, “Global nutrition transition and the pandemic of obesity in developing countries,” Nutrition Reviews, vol. 70, no. 1, pp. 3–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Carotenuto, N. Santoro, A. Grandone et al., “The insulin gene variable number of tandem repeats (INS VNTR) genotype and sleep disordered breathing in childhood obesity,” Journal of Endocrinological Investigation, vol. 32, no. 9, pp. 752–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. NHLBI, “Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report,” Tech. Rep. 98-4083, 1998. View at Google Scholar
  11. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Diabetes trends in the U.S.: 1990–1998,” Diabetes Care, vol. 23, no. 9, pp. 1278–1283, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. K. O'Dea, “Overview of the thrifty genotype hypothesis,” Asia Pacific Journal of Clinical Nutrition, vol. 4, pp. 339–340, 1995. View at Google Scholar
  13. C. Diéguez, M. J. Vazquez, A. Romero, M. López, and R. Nogueiras, “Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins,” Neuroendocrinology, vol. 94, no. 1, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Lage, C. Diéguez, A. Vidal-Puig, and M. López, “AMPK: a metabolic gauge regulating whole-body energy homeostasis,” Trends in Molecular Medicine, vol. 14, no. 12, pp. 539–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Guyenet and M. W. Schwartz, “Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 3, pp. 745–755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Al-Massadi, A. B. Crujeiras, R. C. González et al., “Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 299, no. 3, pp. E341–E350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. E. Sawchenko, “Central connections of the sensory and motor nuclei of the vagus nerve,” Journal of the Autonomic Nervous System, vol. 9, no. 1, pp. 13–26, 1983. View at Publisher · View at Google Scholar · View at Scopus
  18. S. J. Konturek, T. Brzozowski, P. C. Konturek et al., “Brain-gut and appetite regulating hormones in the control of gastric secretion and mucosal protection,” Journal of Physiology and Pharmacology, vol. 59, no. 2, pp. 7–31, 2008. View at Google Scholar · View at Scopus
  19. H.-R. Berthoud, “The vagus nerve, food intake and obesity,” Regulatory Peptides, vol. 149, no. 1–3, pp. 15–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. T. Neary and R. L. Batterham, “Gut hormones: implications for the treatment of obesity,” Pharmacology & Therapeutics, vol. 124, no. 1, pp. 44–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Folgueira, L. M. Seoane, and F. F. Casanueva, “The brain-stomach connection,” Frontiers of Hormone Research, vol. 42, pp. 83–92, 2014. View at Google Scholar
  22. D. Cota, G. Marsicano, B. Lutz et al., “Endogenous cannabinoid system as a modulator of food intake,” International Journal of Obesity and Related Metabolic Disorders, vol. 27, no. 3, pp. 289–301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. R. Pazos, R. M. Tolón, C. Benito et al., “Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa,” The Journal of Histochemistry and Cytochemistry, vol. 56, no. 5, pp. 511–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, “Ghrelin is a growth-hormone-releasing acylated peptide from stomach,” Nature, vol. 402, no. 6762, pp. 656–660, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Date, M. Kojima, H. Hosoda et al., “Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans,” Endocrinology, vol. 141, no. 11, pp. 4255–4261, 2000. View at Google Scholar · View at Scopus
  26. O. Al Massadi, M. H. Tschöp, and J. Tong, “Ghrelin acylation and metabolic control,” Peptides, vol. 32, no. 11, pp. 2301–2308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Ariyasu, K. Takaya, T. Tagami et al., “Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 10, pp. 4753–4758, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Inui, A. Asakawa, C. Y. Bowers et al., “Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ,” The FASEB Journal, vol. 18, no. 3, pp. 439–456, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Seoane, O. Al-Massadi, F. Barreiro, C. Dieguez, and F. F. Casanueva, “Growth hormone and somatostatin directly inhibit gastric ghrelin secretion. An in vitro organ culture system,” Journal of Endocrinological Investigation, vol. 30, no. 9, pp. RC22–RC25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. M. Wren and S. R. Bloom, “Gut hormones and appetite control,” Gastroenterology, vol. 132, no. 6, pp. 2116–2130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. L. M. Seoane, O. Al-Massadi, J. E. Caminos, S. A. Tovar, C. Dieguez, and F. F. Casanueva, “Sensory stimuli directly acting at the central nervous system regulate gastric ghrelin secretion. An ex vivo organ culture study,” Endocrinology, vol. 148, no. 8, pp. 3998–4006, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Tschöp, C. Weyer, P. A. Tataranni, V. Devanarayan, E. Ravussin, and M. L. Heiman, “Circulating ghrelin levels are decreased in human obesity,” Diabetes, vol. 50, no. 4, pp. 707–709, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. T. K. Hansen, R. Dall, H. Hosoda et al., “Weight loss increases circulating levels of ghrelin in human obesity,” Clinical Endocrinology, vol. 56, no. 2, pp. 203–206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. H. R. Kissileff, F. X. Pi-Sunyer, J. Thornton, and G. P. Smith, “C-terminal octapeptide of cholecystokinin decreases food intake in man,” The American Journal of Clinical Nutrition, vol. 34, no. 2, pp. 154–160, 1981. View at Google Scholar · View at Scopus
  35. R. C. Ritter, M. Covasa, and C. A. Matson, “Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight,” Neuropeptides, vol. 33, no. 5, pp. 387–399, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. F. A. Duca and M. Covasa, “Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity,” The British Journal of Nutrition, vol. 108, no. 5, pp. 778–793, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Zwirska-Korczala, S. J. Konturek, M. Sodowski et al., “Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome,” Journal of Physiology and Pharmacology, vol. 58, no. 1, pp. 13–35, 2007. View at Google Scholar · View at Scopus
  38. J.-F. Gautier, S.-P. Choukem, and J. Girard, “Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes,” Diabetes & Metabolism, vol. 34, supplement 2, pp. S65–S72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Kreymann, G. Williams, M. A. Ghatei, and S. R. Bloom, “Glucagon-like peptide-1 7-36: a physiological incretin in man,” The Lancet, vol. 2, no. 8571, pp. 1300–1304, 1987. View at Google Scholar · View at Scopus
  40. R. M. Elliott, L. M. Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks, “Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns,” The Journal of Endocrinology, vol. 138, no. 1, pp. 159–166, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Adamska, L. Ostrowska, M. Goŕska, and A. Kreţowski, “The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes,” Przeglad Gastroenterologiczny, vol. 9, no. 2, pp. 69–76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. L. L. Baggio and D. J. Drucker, “Biology of Incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. E. Kanoski, S. M. Fortin, M. Arnold, H. J. Grill, and M. R. Hayes, “Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4,” Endocrinology, vol. 152, no. 8, pp. 3103–3112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. D. A. D'Alessio, D. A. Sandoval, and R. J. Seeley, “New ways in which GLP-1 can regulate glucose homeostasis,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3406–3408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Rodriguez de Fonseca, M. Navarro, E. Alvarez et al., “Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats,” Metabolism: Clinical and Experimental, vol. 49, no. 6, pp. 709–717, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. C. R. Abbott, M. Monteiro, C. J. Small et al., “The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway,” Brain Research, vol. 1044, no. 1, pp. 127–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. P. K. Chelikani, A. C. Haver, and R. D. Reidelberger, “Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 288, no. 6, pp. R1695–R1706, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. E. B. Rüttimann, M. Arnold, J. J. Hillebrand, N. Geary, and W. Langhans, “Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms,” Endocrinology, vol. 150, no. 3, pp. 1174–1181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. K. A. Scott and T. H. Moran, “The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 293, no. 3, pp. R983–R987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Näslund, M. Gutniak, S. Skogar, S. Rössner, and P. M. Hellström, “Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men,” The American Journal of Clinical Nutrition, vol. 68, no. 3, pp. 525–530, 1998. View at Google Scholar · View at Scopus
  52. J. P. Gutzwiller, J. Drewe, B. Göke et al., “Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 276, no. 5, pp. R1541–R1544, 1999. View at Google Scholar · View at Scopus
  53. A. Flint, A. Raben, A. Astrup, and J. J. Holst, “Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans,” The Journal of Clinical Investigation, vol. 101, no. 3, pp. 515–520, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Flint, A. Raben, A. K. Ersbøll, J. J. Holst, and A. Astrup, “The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity,” International Journal of Obesity and Related Metabolic Disorders, vol. 25, no. 6, pp. 781–792, 2001. View at Google Scholar · View at Scopus
  55. C. Verdich, A. Flint, J.-P. Gutzwiller et al., “A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4382–4389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Fukase, M. Igarashi, H. Takahashi et al., “Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients,” Diabetic Medicine, vol. 10, no. 1, pp. 44–49, 1993. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Vilsbøll, T. Krarup, J. Sonne et al., “Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2706–2713, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Verdich, S. Toubro, B. Buemann, J. Lysgård Madsen, J. Juul Holst, and A. Astrup, “The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction,” International Journal of Obesity and Related Metabolic Disorders, vol. 25, no. 8, pp. 1206–1214, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. L. R. Ranganath, J. M. Beety, L. M. Morgan, J. W. Wright, R. Howland, and V. Marks, “Attenuated GLP-1 secretion in obesity: cause or consequence?” Gut, vol. 38, no. 6, pp. 916–919, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. P. J. Tomasik, K. Sztefko, and A. Malek, “GLP-1 as a satiety factor in children with eating disorders,” Hormone and Metabolic Research, vol. 34, no. 2, pp. 77–80, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Lugari, A. Dei Cas, D. Ugolotti et al., “Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion,” Hormone and Metabolic Research, vol. 36, no. 2, pp. 111–115, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M.-B. Toft-Nielsen, M. B. Damholt, S. Madsbad et al., “Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3717–3723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. A. A. Vaag, J. J. Holst, A. Vølund, and H. Beck-Nielsen, “Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins,” European Journal of Endocrinology, vol. 135, no. 4, pp. 425–432, 1996. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Muscelli, A. Mari, A. Casolaro et al., “Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients,” Diabetes, vol. 57, no. 5, pp. 1340–1348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. I. S. Oh, H. Shimizu, T. Satoh et al., “Identification of nesfatin-1 as a satiety molecule in the hypothalamus,” Nature, vol. 443, no. 7112, pp. 709–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Goebel-Stengel and L. Wang, “Central and peripheral expression and distribution of NUCB2/nesfatin-1,” Current Pharmaceutical Design, vol. 19, no. 39, pp. 6935–6940, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Stengel, M. Mori, and Y. Taché, “The role of nesfatin-1 in the regulation of food intake and body weight: Recent developments and future endeavors,” Obesity Reviews, vol. 14, no. 11, pp. 859–870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Stengel, M. Goebel, and Y. Taché, “Nesfatin-1: a novel inhibitory regulator of food intake and body weight,” Obesity Reviews, vol. 12, no. 4, pp. 261–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. D. García-Galiano and M. Tena-Sempere, “Emerging roles of NUCB2/Nesfatin-1 in the metabolic control of reproduction,” Current Pharmaceutical Design, vol. 19, no. 39, pp. 6966–6972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. B. K. Tan, M. Hallschmid, W. Kern, H. Lehnert, and H. S. Randeva, “Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 4, pp. E669–E673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Ramanjaneya, J. Chen, J. E. Brown et al., “Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity,” Endocrinology, vol. 151, no. 7, pp. 3169–3180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. H. Walsh, “Role of gastrin as a trophic hormone,” Digestion, vol. 47, supplement 1, pp. 11–16, 49–52, 1990. View at Google Scholar
  73. J. F. Rehfeld and F. Stadil, “The effect of gastrin on basal- and glucose-stimulated insulin secretion in man,” The Journal of Clinical Investigation, vol. 52, no. 6, pp. 1415–1426, 1973. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Adami, P. Frati, S. Bertini et al., “Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach,” British Journal of Pharmacology, vol. 135, no. 7, pp. 1598–1606, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Coruzzi, M. Adami, G. Coppelli, P. Frati, and G. Soldani, “Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 360, no. 6, pp. 715–718, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Adami, R. Zamfirova, E. Sotirov et al., “Gastric antisecretory effects of synthetic cannabinoids after central or peripheral administration in the rat,” Brain Research Bulletin, vol. 64, no. 4, pp. 357–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. R. S. Ahima and J. S. Flier, “Leptin,” Annual Review of Physiology, vol. 62, pp. 413–437, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. L. M. Seoane, M. López, S. Tovar, F. F. Casanueva, R. Señarís, and C. Diéguez, “Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus,” Endocrinology, vol. 144, no. 2, pp. 544–551, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. A. T. Turer and P. E. Scherer, “Adiponectin: mechanistic insights and clinical implications,” Diabetologia, vol. 55, no. 9, pp. 2319–2326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Fruebis, T.-S. Tsao, S. Javorschi et al., “Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 4, pp. 2005–2010, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Kishida, T. Funahashi, and I. Shimomura, “Adiponectin as a routine clinical biomarker,” Best Practice & Research: Clinical Endocrinology and Metabolism, vol. 28, no. 1, pp. 119–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Blüher, “Adipokines—removing road blocks to obesity and diabetes therapy,” Molecular Metabolism, vol. 3, no. 3, pp. 230–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. N. M. Delzenne and P. D. Cani, “Interaction between obesity and the gut microbiota: relevance in nutrition,” Annual Review of Nutrition, vol. 31, pp. 15–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Bäckhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15718–15723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007. View at Google Scholar
  86. P. D. Cani, R. Bibiloni, C. Knauf et al., “Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice,” Diabetes, vol. 57, no. 6, pp. 1470–1481, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. P. D. Cani, S. Possemiers, T. van de Wiele et al., “Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability,” Gut, vol. 58, no. 8, pp. 1091–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027–1031, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. P. J. Turnbaugh, F. Bäckhed, L. Fulton, and J. I. Gordon, “Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome,” Cell Host & Microbe, vol. 3, no. 4, pp. 213–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. E. F. Murphy, P. D. Cotter, S. Healy et al., “Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models,” Gut, vol. 59, no. 12, pp. 1635–1642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Geurts, V. Lazarevic, M. Derrien et al., “Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: Impact on apelin regulation in adipose tissue,” Frontiers in Microbiology, vol. 2, article 149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. R. E. Ley, D. A. Peterson, and J. I. Gordon, “Ecological and evolutionary forces shaping microbial diversity in the human intestine,” Cell, vol. 124, no. 4, pp. 837–848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. J.-P. Furet, L.-C. Kong, J. Tap et al., “Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers,” Diabetes, vol. 59, no. 12, pp. 3049–3057, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. G. G. Muccioli, D. Naslain, F. Bäckhed et al., “The endocannabinoid system links gut microbiota to adipogenesis,” Molecular Systems Biology, vol. 6, article 392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. R. F. Kushner, “Weight loss strategies for treatment of obesity,” Progress in Cardiovascular Diseases, vol. 56, no. 4, pp. 465–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. M. L. Dansinger, J. A. Gleason, J. L. Griffith, H. P. Selker, and E. J. Schaefer, “Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction: a randomized trial,” Journal of the American Medical Association, vol. 293, no. 1, pp. 43–53, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. E. S. Leblanc, E. O'Connor, E. P. Whitlock, C. D. Patnode, and T. Kapka, “Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 155, no. 7, pp. 434–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Blüher, “Clinical relevance of adipokines,” Diabetes & Metabolism Journal, vol. 36, no. 5, pp. 317–327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Z. Yanovski and J. A. Yanovski, “Long-term drug treatment for obesity: a systematic and clinical review,” Journal of the American Medical Association, vol. 311, no. 1, pp. 74–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. T. D. Müller, L. M. Sullivan, K. Habegger et al., “Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21,” Journal of Peptide Science, vol. 18, no. 6, pp. 383–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. J. T. Heiker, N. Klöting, P. Kovacs et al., “Vaspin inhibits kallikrein 7 by serpin mechanism,” Cellular and Molecular Life Sciences, vol. 70, no. 14, pp. 2569–2583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Cantó and J. Auwerx, “PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure,” Current Opinion in Lipidology, vol. 20, no. 2, pp. 98–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. L. L. Senin, O. Al-Massadi, C. Folgueira et al., “The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake,” PLoS ONE, vol. 8, no. 11, Article ID e80339, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Caixas, L. Albert, I. Capel, and M. Rigla, “Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date,” Drug Design, Development and Therapy, vol. 8, pp. 1419–1427, 2014. View at Publisher · View at Google Scholar
  105. S. Barja-Fenández, R. Leis, F. F. Casanueva, and L. M. Seoane, “Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss,” Drug Design, Development and Therapy, no. 8, pp. 2391–2400, 2014. View at Publisher · View at Google Scholar
  106. “Gastrointestinal surgery for severe obesity: National Institutes of Health consensus development conference statement,” The American Journal of Clinical Nutrition, vol. 55, no. 2, supplement, pp. 615S–619S, 1992.
  107. A. D. Miras and C. W. le Roux, “Mechanisms underlying weight loss after bariatric surgery,” Nature Reviews. Gastroenterology & Hepatology, vol. 10, no. 10, pp. 575–584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. V. Ionut, M. Burch, A. Youdim, and R. N. Bergman, “Gastrointestinal hormones and bariatric surgery-induced weight loss,” Obesity, vol. 21, no. 6, pp. 1093–1103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. J. B. Dixon, C. W. le Roux, F. Rubino, and P. Zimmet, “Bariatric surgery for type 2 diabetes,” The Lancet, vol. 379, no. 9833, pp. 2300–2311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. L. M. S. Carlsson, M. Peltonen, S. Ahlin et al., “Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects,” The New England Journal of Medicine, vol. 367, no. 8, pp. 695–704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Scholtz, A. D. Miras, N. Chhina et al., “Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding,” Gut, vol. 63, no. 6, pp. 891–902, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. I. Melnikova and D. Wages, “Anti-obesity therapies,” Nature Reviews Drug Discovery, vol. 5, no. 5, pp. 369–370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Topart, G. Becouarn, A. Sallé, and P. Ritz, “Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery,” Surgery for Obesity and Related Diseases, vol. 10, no. 5, pp. 936–941, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. H. P. Santry, D. L. Gillen, and D. S. Lauderdale, “Trends in bariatric surgical procedures,” The Journal of the American Medical Association, vol. 294, no. 15, pp. 1909–1917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Sjöström, M. Peltonen, P. Jacobson et al., “Bariatric surgery and long-term cardiovascular events,” Journal of the American Medical Association, vol. 307, no. 1, pp. 56–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. M. A. Stefater, H. E. Wilson-Pérez, A. P. Chambers, D. A. Sandoval, and R. J. Seeley, “All bariatric surgeries are not created equal: insights from mechanistic comparisons,” Endocrine Reviews, vol. 33, no. 4, pp. 595–622, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Osto, K. Abegg, M. Bueter, C. W. le Roux, P. D. Cani, and T. A. Lutz, “Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine,” Physiology & Behavior, vol. 119, pp. 92–96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Gass, C. Beglinger, and R. Peterli, “Metabolic surgery-principles and current concepts,” Langenbeck's Archives of Surgery, vol. 396, no. 7, pp. 949–972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. I. J. Hatoum, D. M. Greenawalt, C. Cotsapas, M. L. Reitman, M. J. Daly, and L. M. Kaplan, “Heritability of the weight loss response to gastric bypass surgery,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 10, pp. E1630–E1633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Auguet, X. Terra, M. Hernández et al., “Clinical and adipocytokine changes after bariatric surgery in morbidly obese women,” Obesity, vol. 22, no. 1, pp. 188–194, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. R. Peterli, B. Wölnerhanssen, T. Peters et al., “Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial,” Annals of Surgery, vol. 250, no. 2, pp. 234–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Nannipieri, S. Baldi, A. Mari et al., “Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 11, pp. 4391–4399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. X. Terra, T. Auguet, E. Guiu-Jurado et al., “Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy,” Obesity Surgery, vol. 23, no. 11, pp. 1790–1798, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Yousseif, J. Emmanuel, E. Karra et al., “Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans,” Obesity Surgery, vol. 24, no. 2, pp. 241–252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. W.-J. Lee, C.-Y. Chen, K. Chong, Y.-C. Lee, S.-C. Chen, and S.-D. Lee, “Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy,” Surgery for Obesity and Related Diseases, vol. 7, no. 6, pp. 683–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. C. Holdstock, B. E. Engström, M. Öhrvall, L. Lind, M. Sundbom, and F. A. Karlsson, “Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 3177–3183, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. A. F. R. Dixon, J. B. Dixon, and P. E. O'Brien, “Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 2, pp. 813–819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. R. Stoeckli, R. Clianda, I. Langer, and U. Keller, “Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass,” Obesity Research, vol. 12, no. 2, pp. 346–350, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. A. C. Krieger, H. Youn, F. Modersitzki et al., “Effects of laparoscopic adjustable gastric banding on sleep and metabolism: a 12-month follow-up study,” International Journal of General Medicine, vol. 5, pp. 975–981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Korner, W. Inabnet, G. Febres et al., “Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass,” International Journal of Obesity, vol. 33, no. 7, pp. 786–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. F. Rodieux, V. Giusti, D. A. D'Alessio, M. Suter, and L. Tappy, “Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release,” Obesity (Silver Spring), vol. 16, no. 2, pp. 298–305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Dimitriadis, M. Daskalakis, M. Kampa, A. Peppe, J. A. Papadakis, and J. Melissas, “Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study,” Annals of Surgery, vol. 257, no. 4, pp. 647–654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Tsoli, A. Chronaiou, I. Kehagias, F. Kalfarentzos, and T. K. Alexandrides, “Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study,” Surgery for Obesity and Related Diseases, vol. 9, no. 5, pp. 667–677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. T. E. Sweeney and J. M. Morton, “Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature,” Best Practice & Research. Clinical Gastroenterology, vol. 28, pp. 727–740, 2014. View at Google Scholar
  135. L. Ockander, J. L. Hedenbro, J. F. Rehfeld, and K. Sjölund, “Jejunoileal bypass changes the duodenal cholecystokinin and somatostatin cell density,” Obesity Surgery, vol. 13, no. 4, pp. 584–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. C. B. Chan, A. M. J. Buchan, K. A. Green, and R. A. Pederson, “The effect of jejunoileal bypass (JIB) in the obese Zucker rat on a sub-group of enteroendocrine cells,” International Journal of Obesity, vol. 11, no. 3, pp. 285–293, 1987. View at Google Scholar · View at Scopus
  137. A. M. J. Buchan, R. A. Pederson, I. Koop, R. H. Gourlay, and I. G. M. Cleator, “Morphological and functional alterations to a sub-group of regulatory peptides in human pancreas and intestine after jejuno-ileal bypass,” International Journal of Obesity, vol. 17, no. 2, pp. 109–113, 1993. View at Google Scholar · View at Scopus
  138. E. Näslund, P. Grybäck, P. M. Hellström et al., “Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity,” International Journal of Obesity, vol. 21, no. 5, pp. 387–392, 1997. View at Publisher · View at Google Scholar · View at Scopus
  139. J. M. Kellum, J. F. Kuemmerle, T. M. O'Dorisio et al., “Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty,” Annals of Surgery, vol. 211, no. 6, pp. 763–770, 1990. View at Publisher · View at Google Scholar · View at Scopus
  140. S. H. Jacobsen, S. C. Olesen, C. Dirksen et al., “Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects,” Obesity Surgery, vol. 22, no. 7, pp. 1084–1096, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. R. Peterli, R. E. Steinert, B. Woelnerhanssen et al., “Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial,” Obesity Surgery, vol. 22, no. 5, pp. 740–748, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. C. P. de Carvalho, D. M. Marin, A. L. de Souza et al., “GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism,” Obesity Surgery, vol. 19, no. 3, pp. 313–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Evans, Z. Pamuklar, J. Rosko et al., “Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction,” Surgical Endoscopy and Other Interventional Techniques, vol. 26, no. 4, pp. 1086–1094, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. W.-J. Lee, C.-Y. Chen, K.-H. Ser et al., “Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus,” Current Pharmaceutical Design, vol. 19, no. 32, pp. 5830–5835, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. E. Grong, I. B. Arbo, O. K. Thu, E. Kuhry, B. Kulseng, and R. Mårvik, “The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats,” Surgical Endoscopy, vol. 29, no. 3, pp. 723–733, 2015. View at Publisher · View at Google Scholar
  146. T. Sillakivi, J. Suumann, Ü. Kirsimägi, and A. Peetsalu, “Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery,” Hepato-Gastroenterology, vol. 60, no. 128, pp. 2129–2132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. J. R. Shak, J. Roper, G. I. Perez-Perez et al., “The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones,” Obesity Surgery, vol. 18, no. 9, pp. 1089–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. N. Basso, D. Capoccia, M. Rizzello et al., “First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: The gastric hypothesis,” Surgical Endoscopy, vol. 25, no. 11, pp. 3540–3550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. N. G. de la Torre, M. A. Rubio, E. Bordiú et al., “Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 11, pp. 4276–4281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  150. B. Woelnerhanssen, R. Peterli, R. E. Steinert, T. Peters, Y. Borbély, and C. Beglinger, “Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial,” Surgery for Obesity and Related Diseases, vol. 7, no. 5, pp. 561–568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. G. Frühbeck, A. Diez-Caballero, J. Gómez-Ambrosi et al., “Disruption of the leptin-insulin relationship in obese men 24 hours after laparoscopic adjustable silicone gastric banding,” Obesity Surgery, vol. 12, no. 3, pp. 366–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  152. P. Maruna, R. Gürlich, M. Fried, R. Frasko, I. Chachkhiani, and M. Haluzik, “Leptin as an acute phase reactant after non-adjustable laparoscopic gastric banding,” Obesity Surgery, vol. 11, no. 5, pp. 609–614, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. M. A. Trakhtenbroit, J. G. Leichman, M. F. Algahim et al., “Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery,” The American Journal of Medicine, vol. 122, no. 5, pp. 435–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. F. Carrasco, K. Basfi-Fer, P. Rojas et al., “Changes in bone mineral density after sleeve Gastrectomy or gastric bypass: relationships with variations in vitamin D, ghrelin, and adiponectin levels,” Obesity Surgery, vol. 24, no. 6, pp. 877–884, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. C. C. Coughlin, B. N. Finck, J. C. Eagon et al., “Effect of marked weight loss on adiponectin gene expression and plasma concentrations,” Obesity, vol. 15, no. 3, pp. 640–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. M. M. Swarbrick, I. T. Austrheim-Smith, K. L. Stanhope et al., “Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery,” Diabetologia, vol. 49, no. 11, pp. 2552–2558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. C. Shrestha, H. He, Y. Liu, S. Zhu, J. Xiong, and Z. Mo, “Changes in adipokines following laparoscopic Roux-en-Y gastric bypass surgery in Chinese individuals with type 2 diabetes mellitus and BMI of 22–30 kg·m−2,” International Journal of Endocrinology, vol. 2013, Article ID 240971, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. L. M. Umeda, A. Z. Pereira, G. Carneiro, C. H. Arasaki, and M. T. Zanella, “Postprandial adiponectin levels are associated with improvements in postprandial triglycerides after Roux-en-Y gastric bypass in type 2 diabetic patients,” Metabolic Syndrome and Related Disorders, vol. 11, no. 5, pp. 343–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  159. J. V. Li, H. Ashrafian, M. Bueter et al., “Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk,” Gut, vol. 60, no. 9, pp. 1214–1223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. H. Zhang, J. K. DiBaise, A. Zuccolo et al., “Human gut microbiota in obesity and after gastric bypass,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2365–2370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. J. V. Li, R. Reshat, Q. Wu et al., “Experimental bariatric surgery in rats generates a cytotoxic chemical environment in the gut contents,” Frontiers in Microbiology, vol. 2, article 183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. A. P. Liou, M. Paziuk, J.-M. Luevano Jr., S. Machineni, P. J. Turnbaugh, and L. M. Kaplan, “Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity,” Science Translational Medicine, vol. 5, no. 178, Article ID 178ra41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Graessler, Y. Qin, H. Zhong et al., “Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,” The Pharmacogenomics Journal, vol. 13, no. 6, pp. 514–522, 2013. View at Publisher · View at Google Scholar · View at Scopus